McDermott Advises Owkin on a Strategic Collaboration with Sanofi


McDermott Will & Emery advised Owkin, an artificial intelligence and precision medicine company, on a new strategic collaboration with Sanofi, with the aim of discovery and development programmes in four exclusive types of cancer.

Intending to optimize clinical trial design and detect predictive biomarkers, this collaboration will support Sanofi’s oncology portfolio in core areas such as lung cancer, breast cancer and multiple myeloma.

Alongside the strategic collaboration, Sanofi also announced an equity investment of USD 180 million, valuating the startup at more than USD 1 billion and making Owkin a unicorn company.

The McDermott team that advised Owkin comprised:

  • Emmanuelle Trombe et Anne-France Moreau, partners, and Lorraine Maisnier-Boché, associate

About McDermott

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices, industries and more than 20 locations to deliver highly effective—and often unexpected—solutions that propel success. More than 1,200 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.